UTAA09 injection for relapsed or refractory blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational cell therapy called UTAA09 for people with CD19-positive B-cell blood cancers that have come back or not responded to treatment. It aims to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 70 years old.
- You have a CD19-positive B-cell blood cancer that has relapsed or is refractory (did not respond to treatment).
- Your doctor expects you to live longer than 12 weeks.
- You are able to do daily activities with little or no help (ECOG score 0-2).
- Your heart, liver, kidneys, and lungs are working well enough based on blood tests and other checks.
- You agree to participate and sign a consent form after understanding the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
This study tests a new cell therapy called UTAA91 for people with moderate to severe rheumatoid arthritis that hasn't improved with standard treatments. The goal is to see if this treatment can help reduce symptoms and improve quality of life.
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Hear when a new CD19-positive Relapsed or Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.